1.	To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00097, 2011-004701-24, NCT01496313
2.	ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and older Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00032, 6474IL/0032, NCT00312377
3.	Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00057, EUDRACT No. 2006-000259-16, NCT00364351
4.	An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00058, NCT00410761
5.	ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00044, EUDRACT Number 2006-002384-12, NCT00404924
6.	Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00036, EUDRACT No. 2006-003695-35, NCT00418886
7.	Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment Phase: Phase III Type: Natural history/Epidemiology, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00088, 2010-023428-26, NCT01298323
8.	Phase I/II Study of ZD6474 in Patients With Recurrent High-Grade or Progressive Low-Grade Gliomas Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-06-C-0063, NCI-P6680, NCT00293566
9.	Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 06-377, IRUSZACT0018, NCT00441142
10.	A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroi... Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 80 Sponsor: NCI Protocol IDs: 090089, 09-C-0089, NCT00923247
11.	Phase II Study of ZD6474 in Patients With Relapsed Multiple Myeloma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-IND145, ZENECA-6474IL/0004, IND145
12.	Phase II Randomized Study of ZD6474 Versus Gefitinib (ZD1839) in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Who Failed Prior First-Line Platinum-Based Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-03090, ZENECA-6474IL/0003, NCT00059722
13.	Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00008, NCT00098345
14.	A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00068, NCT00358956
15.	BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 2005-0825, NCT00410189
16.	A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00048, NCT00454116
17.	Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 06-283, NCT00459043
18.	Malignant Pleural Effusion With ZD6474 Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2005-0929, NCT00402896
19.	A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00047, NCT00500292
20.	Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) Phase: Phase II Type: Treatment Status: Completed Age: 20 to 120 Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00072, NCT00508001
21.	Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer Phase: Phase II Type: Tissue collection/Repository, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00079, NCT00537095
22.	Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: LUN06-113, NCT00613626
23.	Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00080, NCT00659438
24.	Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PrE0501, IRUSZACT0088, NCT00687297
25.	Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000599867, RTOG-0619, NCT00720083